The benefits of immunotherapy combinations
This article, published in Nature just before Christmas, gives a [...]
Lenvatinib plus pembrolizumab combination designated a breakthrough therapy by the FDA
The US Food and Drug Administration (FDA) have granted Breakthrough [...]
Pembrolizumab investigated as adjuvant therapy for renal cell carcinoma
Immunotherapy has been a major breakthrough in the treatment of [...]
The evolving management of advanced renal cell carcinoma
This article, published in UroToday this week, is a nice summary [...]
Neoadjuvant and adjuvant therapy for renal cell carcinoma: critique, current trials and future directions
The following articles discuss the use of neoadjuvant therapy (drug [...]
European Society of Medical Oncology (ESMO) highlights from the IKCC
The International Kidney Cancer Coalition (IKCC) had a booth at [...]
Lenvatinib plus pembrolizumab combination shows promise in advanced kidney cancer
Interim results from Study 111, a phase Ib/II clinical trial [...]
Combining radiotherapy with immunotherapy – a review of past, present and future developments
New immunotherapy treatments are currently revolutionising the field of oncology [...]
Cancer Drugs Fund driving early access to promising new treatments
The National Institute for Health and Care Excellence (NICE) has [...]
Novel treatment options for kidney cancer presented at ASCO 2017
The following video is an interview between PracticeUpdate and Dr Bradley [...]
